GlassScriptPhysician profile
Brad Russell Johnson
NPI 1538165295
$12,726.30
in general payments reported to CMS, 2019-2025
33 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 78% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,367 · 2021: $1,954 · 2022: $1,682 · 2023: $2,382 · 2024: $1,444 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.58 | 2019-2025 | |
| Amgen INC. | $1,345.63 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,094.97 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,037.91 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $910.03 | 2019-2025 | |
| Dermavant Sciences, INC. | $893.06 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $887.17 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $858.47 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $531.88 | 2019-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $469.91 | 2019-2025 | Nemluvio |
| Ucb, INC. | $373.23 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $369.75 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $346.83 | 2023-2025 | Zoryve |
| Organon LLC | $302.86 | 2025 | Vtama, Jada System |
| Vyne Pharmaceuticals INC. | $277.72 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $209.83 | 2019-2024 | |
| Celgene Corporation | $190.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $158.95 | 2022-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.45 | 2019-2024 | Siliq |
| Leo Pharma INC. | $154.76 | 2021-2024 | Adbry |
| Prugen, INC. Pharmaceuticals | $152.70 | 2019 | |
| Mayne Pharma Commercial LLC | $137.94 | 2021-2025 | |
| Biofrontera INC. | $83.95 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $78.49 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $54.56 | 2019 | |
| Aclaris Therapeutics, INC. | $47.35 | 2019 | |
| Kerecis Limited | $40.61 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Kyowa Kirin, INC. | $32.87 | 2021-2025 | |
| Dermira, INC. | $24.74 | 2019 | |
| Genentech USA, INC. | $24.07 | 2019 | |
| Janssen Scientific Affairs, LLC | $21.03 | 2020 | |
| Sandoz INC. | $18.22 | 2023 | Hyrimoz |
| Almirall LLC | $16.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.